JP2018508571A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508571A5
JP2018508571A5 JP2017560858A JP2017560858A JP2018508571A5 JP 2018508571 A5 JP2018508571 A5 JP 2018508571A5 JP 2017560858 A JP2017560858 A JP 2017560858A JP 2017560858 A JP2017560858 A JP 2017560858A JP 2018508571 A5 JP2018508571 A5 JP 2018508571A5
Authority
JP
Japan
Prior art keywords
seq
sequence
glp
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508571A (ja
JP6731953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/073279 external-priority patent/WO2016127887A1/zh
Publication of JP2018508571A publication Critical patent/JP2018508571A/ja
Publication of JP2018508571A5 publication Critical patent/JP2018508571A5/ja
Application granted granted Critical
Publication of JP6731953B2 publication Critical patent/JP6731953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560858A 2015-02-11 2016-02-03 Glp−1r抗体融合タンパク質の安定な医薬溶液製剤 Active JP6731953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510071304.1 2015-02-11
CN201510071304 2015-02-11
PCT/CN2016/073279 WO2016127887A1 (zh) 2015-02-11 2016-02-03 一种药用glp-1r抗体融合蛋白的稳定溶液制剂

Publications (3)

Publication Number Publication Date
JP2018508571A JP2018508571A (ja) 2018-03-29
JP2018508571A5 true JP2018508571A5 (enExample) 2020-06-18
JP6731953B2 JP6731953B2 (ja) 2020-07-29

Family

ID=56615305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560858A Active JP6731953B2 (ja) 2015-02-11 2016-02-03 Glp−1r抗体融合タンパク質の安定な医薬溶液製剤

Country Status (11)

Country Link
US (1) US10485870B2 (enExample)
EP (1) EP3257524B1 (enExample)
JP (1) JP6731953B2 (enExample)
KR (1) KR102568272B1 (enExample)
CN (2) CN121927035A (enExample)
AU (1) AU2016218759B2 (enExample)
DK (1) DK3257524T3 (enExample)
ES (1) ES2833099T3 (enExample)
PL (1) PL3257524T3 (enExample)
PT (1) PT3257524T (enExample)
WO (1) WO2016127887A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7239566B2 (ja) 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド1受容体アゴニストおよびそれらの使用
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
KR20260047627A (ko) * 2022-10-19 2026-04-08 일라이 릴리 앤드 캄파니 보존된 gip/glp 효능제 조성물
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁(杭州)生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US5899883A (en) 1998-07-08 1999-05-04 Jinq Shing Chern Safety syringe
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
NZ524482A (en) * 2000-09-01 2005-11-25 Chugai Pharmaceutical Co Ltd Solution formulations having long-term stability
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
PT1831252E (pt) * 2004-12-22 2009-09-17 Lilly Co Eli Formulações de proteínas de fusão de análogos de glp-1
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
HRP20110242T1 (hr) 2007-07-10 2011-05-31 Eli Lilly And Company Formulacija s fuzijskim proteinom glp-1-fc
US20090021453A1 (en) 2007-07-19 2009-01-22 Zachary Smith Fashion accessory including alternating light emitting and non-light emitting elements of consistent lengths
JP2011503000A (ja) 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド 半合成GLP−1ペプチド−Fc融合コンストラクト、その方法及び使用
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
WO2011056644A2 (en) * 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
CN102961745B (zh) 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质

Similar Documents

Publication Publication Date Title
RU2021134101A (ru) Модифицированная j-цепь
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
IL313003A (en) Tigit- and light-based chimeric proteins
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
JP2018033454A5 (enExample)
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20220708A1 (es) Anticuerpos anti-cd73
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
JP2015212284A5 (enExample)
JP2014224126A5 (enExample)
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
JP2018504907A5 (enExample)
PE20091004A1 (es) Proteinas de union a antigenos c-fms humanos
AR095432A1 (es) Proteínas de unión a antígeno
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
EA201892554A1 (ru) Мутант cd200 и его применения
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20220217A1 (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
MX2018013342A (es) Polipeptido de fusion multicircular "contorsbody" - ligante de diana de cadena sencilla.
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης